Home Biotechnology Global Organoids and Spheroids Market Share and Forecast to 2031

Organoids and Spheroids Market

Organoids and Spheroids Market Size, Share & Trends Analysis Report By Type (Organoids, Neural Organoids, Hepatic Organoids, Intestinal Organoids), By Spheroids (Multicellular Tumor Spheroids (MCTS), Neurospheres, Mammospheres, Hepatospheres , Embryoid bodies), By Application (Developmental Biology, Personalized Medicine, Regenerative Medicine, Disease Pathology Studies, Drug Toxicity and Efficacy Testing), By End-user (Biotechnology and Pharmaceutical Industries, Academic and Research Institutes, Hospitals and Diagnostic Centers) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRBI1267DR
Study Period 2020-2032 CAGR 7.2%
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD XX Billion
Forecast Year 2032 Forecast Year Market Size USD XX Billion
Largest Market North America Fastest Growing Market Asia Pacific
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

Model systems drive biological research by mimicking processes and functions of the body from the molecular to the whole organism level. Organoids and spheroids are cells cultured in three dimensions. By deeper insights, spheroids are often grown from cancer cell lines or tumor biopsies as freely floating cell aggregates in ultra-low attachment plates. In contrast, organoids are derived from tissue stem cells embedded within the matrix. These 3D models find extensive usage in modern means of clinical trials as well as personalized medicine regime.

The recent coronavirus outbreak has surged the usage of the organoid models to study and reveal the COVID-19 virus mechanism, affecting several intestinal cells. Many scientists have already begun using these systems for the testing and identification of promising medications. Further, companies engaged in the development and launch of products are stepping up in the arena.  For instance, Agilent Technologies developed and launched a microplate, Seahorse XFe96 Spheroid Microplates that facilitates cellular energy metabolism measurement in 3D cell culture spheroids with the help of a Seahorse XF analyzer.

Market Dynamics

Technological Developments and Innovations in 3D Spheroid Technology to Drive the Market Growth

Technological interventions, as well as the latest innovations, coupled with 3D model technologies, drive the market growth. For instance, the Cultrex Organoid Progenitor Cells launched by AMS Biotechnology (AMSBIO) can be optimized using different sets of extracellular matrices, facilitating the researchers to direct the cellular activities by controlling the culture micro-environment. Thus, spheroids produced by this technique are used for the modeling of cell invasion from tumor spheroids.

Researchers have further developed a 3D tri-culture model by adding vascular cells and human mesenchymal stem cells (hMSCs) to these spheroids. These efforts have led to the development of a predictive in-vitro model as the tri-cultures exhibit drug response and tumor morphology similar to xenografts. Such studies have propelled the adoption of spheroids and organoids in drug testing and clinical trials.

Rapid acceptance and utilization of spheroid and organoid culture in government-based research bodies, as well as institutional projects, is expected to drive the academic and research institutes segment. One such example is researchers from the Stanley Center for Psychiatric Research (Broad Institute) and Harvard University that created enhanced human brain organoids in June 2019 to strengthen neurological disorder research.

Regional Analysis

North America to Hold the Lion’s Share in the Organoids and Spheroids Market

The rapid rise in the implementation of organoid-based research models in the biotechnology sector of the U.S. and Canada drives the regional market growth. These 3D culture technologies have helped the researchers to overcome restraints faced by 2D cell culture platforms, as 3D spheroids offer a microenvironment that can mimic the properties of human tissue structures. Moreover, the presence of numerous state and federal funding organizations in this region that are motivated to fund such projects is also expected to drive the demand for organoids and spheroids culture systems. For instance, a February 2020 study conducted by the American Association for the Study of Liver Diseases (AASLD) regarding the usage of organoid medicine in hepatology was supported by the AASLD Foundation (Pinnacle Research Award), North American Society of Gastroenterology Hepatology and Nutrition Foundation, and Cincinnati Children’s Research Foundation (Procter Scholar Award).

Report Scope

Report Metric Details
By Type
  1. Organoids
  2. Neural Organoids
  3. Hepatic Organoids
  4. Intestinal Organoids
By Spheroids
  1. Multicellular Tumor Spheroids (MCTS)
  2. Neurospheres
  3. Mammospheres
  4. Hepatospheres 
  5. Embryoid bodies
By Application
  1. Developmental Biology
  2. Personalized Medicine
  3. Regenerative Medicine
  4. Disease Pathology Studies
  5. Drug Toxicity and Efficacy Testing
By End-user
  1. Biotechnology and Pharmaceutical Industries
  2. Academic and Research Institutes
  3. Hospitals and Diagnostic Centers
Company Profiles 3D Biomatrix (The U.S.) 3D Biotek LLC (The U.S.) AMS Biotechnology (Europe) Limited (U.K.) ATCC (The U.S.) Cellesce Ltd. Corning Incorporated (The U.S.) Greiner Bio-One (The U.S.) Hubrecht Organoid Technology (HUB) (the Netherlands) Kuraray (Japan) Lonza (Japan) Merck KGaA (The U.S.) Thermo Fisher Scientific, Inc. (The U.S.)
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

Spheroids Segment to Dominate the Market Based on Rising Its Rising Demand in Cancer Research

In the past few years, spheroid cultures have been witnessing ever-growing demand in the field of drug discovery, toxicology, and cancer research. This is attributed to the fact that spheroids have a similar development pattern as of tumors, and they can be cultured to produce a huge volume of cells with consistent dimensions. They can also be analyzed and counted by the use of a variety of instruments and techniques.

The multicellular tumor spheroids (MCTS) segment, on the other hand, dominates the spheroid segment as it is the most commonly adopted spheroid model for cell culture. In April 2020, a study conducted by researchers of the University of Pittsburgh showed the utilization of MCTS in preclinical cancer drug studies. The study concluded that the utilization of MCTS in oncology drug screening regimes can lead to a better assessment of drug response and give accurate insights.

Organoids Segment Is Expected to Grow with the Highest CAGR

Organoids can potentially be used as in-vitro models for drug discovery. With developments in the organoids segment, the market is expected to garner higher revenue during the forecast period. For instance, MatTek Corporation cultured 3D organotypic structures for the production and commercialization of in-vitro human tissue models. The company has commercialized a diverse product portfolio of bronchial airway (EpiAirway), skin (EpiDerm, EpiDermFT), vaginal (EpiVaginal), and ocular (EpiOcular) epithelium.

The intestinal organoids segment holds the largest share in the organoid segment on account of the increasing availability of commercial model systems and intestinal epithelium analysis methods. In addition, intestinal organoids find applications in the field of cell biology, modeling of diseases, and production and screening of drugs.

Biology Segment to Dominate the Market during the Forecast Period

The biology segment dominates the market during the forecast period. Organoid biology provides a great opportunity to test the basics of human developmental biology, learned through classical methods. In the study of the tissue homeostasis process, lineage determination, and embryonic growth, organoids derived from Induced Pluripotent Stem Cells (iPSCs), and Embryonic Stem Cells (ESCs) have proven to be beneficial. This is because the characteristics of the developmental stages they go through are preserved by organoids. Therefore, these models have been used for the study of the stomach, pancreas, and brain developmental biology.

Collaboration and Strategic Partnerships to Drive the Biotechnology and Pharmaceutical Companies Segment

The biotechnology and pharmaceutical companies segment accounted for the largest market share. Future therapeutic applications of organoids and spheroids have motivated pharmaceutical startups to adopt these products. In addition, the surging use of organoids and spheroids by pharmaceutical entities in preclinical drug discovery is expected to propel segment growth. Further, the collaborations and strategic alliances between key players provide an impetus to the market growth. In October 2019, Hubrecht Organoid Technology (HUB) collaborated with MIMETAS to commercialize Organoids-on-a-Chip technology.

Market Size By Type

Market Size By Type
  • Organoids
  • Neural Organoids
  • Hepatic Organoids
  • Intestinal Organoids
  • Recent Developments

    • In 2020, researchers developed mini lungs using 3D cultured models to study the mechanism of the entry of SARS-CoV-2 and its spread in tissues. Organoids have also been employed to study the defense mechanism of tissues against SARS-CoV-2
    • SCIVAX Corporation developed the Nano Culture Plate (NCP) and Nano Culture Dish (NCD). Spheroids grown on NCP can be used for live imaging under both fluorescence and bright-field microscopes.

    Key Players

    Organoids and Spheroids Market Share of Key Players

    Organoids and Spheroids Market Share of Key Players
    3D Biomatrix (The U.S.) 3D Biotek LLC (The U.S.) AMS Biotechnology (Europe) Limited (U.K.) ATCC (The U.S.) Cellesce Ltd. Corning Incorporated (The U.S.) Greiner Bio-One (The U.S.) Hubrecht Organoid Technology (HUB) (the Netherlands) Kuraray (Japan) Lonza (Japan) Merck KGaA (The U.S.) Thermo Fisher Scientific, Inc. (The U.S.) Others

    Frequently Asked Questions (FAQs)

    What is the growth rate for the Organoids and Spheroids Market?
    Organoids and Spheroids Market size will grow at approx. CAGR of 7.2% during the forecast period.
    Some of the top industry players in Organoids and Spheroids Market are, 3D Biomatrix (The U.S.), 3D Biotek LLC (The U.S.), AMS Biotechnology (Europe) Limited (U.K.), ATCC (The U.S.), Cellesce Ltd., Corning Incorporated (The U.S.), Greiner Bio-One (The U.S.), Hubrecht Organoid Technology (HUB) (the Netherlands), Kuraray (Japan), Lonza (Japan), Merck KGaA (The U.S.), Thermo Fisher Scientific, Inc. (The U.S.), etc.
    North America has been dominating the Organoids and Spheroids Market, accounting for the largest share of the market.
    The Organoids and Spheroids Market has seen the most substantial growth rate in Asia Pacific.
    The global Organoids and Spheroids Market report is segmented as follows: By Type, By Spheroids, ByApplication, By End-user

    We are featured on :